SlideShare une entreprise Scribd logo
1  sur  42
Vasopeptidase Inhibition: A New Direction in Cardiovascular Treatment  . By: Dr. HARMANJIT SINGH  MD STUDENT , GMC , PATIALA
INTRODUCTION ,[object Object],[object Object],[object Object]
[object Object],[object Object]
Risk stratification in patients with hypertension Risk Group A Risk Group B Risk Group C  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Treatment strategies by risk stratification and risk group categories in patients with hypertension  BP stages  (mm Hg)  Treatment Strategy  Risk Group A  Risk Group B  Risk Group C  High-Normal (130-139 / 85-89)  Lifestyle modification  Lifestyle modification  Drug therapy, Lifestyle modification  Stage 1 (140-159 / 90-99)  Lifestyle modification upto 12 months  Lifestyle modification upto 6 months  (patients with multiple factors should receive drug therapy + lifestyle modification) Drug therapy, lifestyle modification  Stage 2 & 3 (> 160 / > 100)  Drug therapy, lifestyle modification  Drug therapy + lifestyle modification  Drug therapy + lifestyle modification
[object Object],[object Object],[object Object]
Renin-Angiotensin System  ,[object Object],[object Object],[object Object]
Figure 1 showing role of RAS system in cardiovascular disease
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],Hope Cntd……
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],Natriuretic Pep Ctnd……
[object Object],[object Object],[object Object],[object Object],[object Object],There is also a forth natriuretic peptide known as dendroaspis natriuretic peptide (DNP), isolated from the venom of the green Mamba snake but little is known about it.
[object Object],[object Object],[object Object]
Figure 2 showing the benefits of inhibiting NEP
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Figure 3 showing combined pathways involved in vasopeptidase inhibition
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Other  Trials ,[object Object]
[object Object],[object Object],[object Object]
 
[object Object],[object Object]
[object Object],[object Object],[object Object]
Adverse effects of VPIs ,[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
Conclusion ,[object Object],[object Object],[object Object]
[object Object]
Thanks

Contenu connexe

Tendances

The Use of Gene Therapy to Treat Type 1 Diabetes Mellitus
The Use of Gene Therapy to Treat Type 1 Diabetes MellitusThe Use of Gene Therapy to Treat Type 1 Diabetes Mellitus
The Use of Gene Therapy to Treat Type 1 Diabetes Mellitus
lauradiaz97
 

Tendances (20)

Recent advances in treatment of diabetics mellitus
Recent advances in  treatment of diabetics mellitusRecent advances in  treatment of diabetics mellitus
Recent advances in treatment of diabetics mellitus
 
Autonomic nervous system-I
Autonomic nervous system-IAutonomic nervous system-I
Autonomic nervous system-I
 
Cholinergic and Anticholinesterase drugs
Cholinergic and Anticholinesterase drugsCholinergic and Anticholinesterase drugs
Cholinergic and Anticholinesterase drugs
 
ANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDESANTISENSE OLIGONUCLEOTIDES
ANTISENSE OLIGONUCLEOTIDES
 
Pharmacogenetics - Pharmacokinetics
Pharmacogenetics  - Pharmacokinetics Pharmacogenetics  - Pharmacokinetics
Pharmacogenetics - Pharmacokinetics
 
Neurosteroids
NeurosteroidsNeurosteroids
Neurosteroids
 
Antianxiety drugs pharmacology
Antianxiety drugs pharmacologyAntianxiety drugs pharmacology
Antianxiety drugs pharmacology
 
Pharmacology of free radicals
Pharmacology of free radicalsPharmacology of free radicals
Pharmacology of free radicals
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
The Use of Gene Therapy to Treat Type 1 Diabetes Mellitus
The Use of Gene Therapy to Treat Type 1 Diabetes MellitusThe Use of Gene Therapy to Treat Type 1 Diabetes Mellitus
The Use of Gene Therapy to Treat Type 1 Diabetes Mellitus
 
Non adrenergic, non-cholinergic (nanc) transmitters
Non adrenergic, non-cholinergic (nanc) transmittersNon adrenergic, non-cholinergic (nanc) transmitters
Non adrenergic, non-cholinergic (nanc) transmitters
 
Antioxidants treatment for diabetes mellitus.pptx
Antioxidants treatment for diabetes mellitus.pptxAntioxidants treatment for diabetes mellitus.pptx
Antioxidants treatment for diabetes mellitus.pptx
 
Antihypertensive drugs
Antihypertensive drugsAntihypertensive drugs
Antihypertensive drugs
 
Class sedatives and hypnotics 2
Class sedatives and hypnotics 2Class sedatives and hypnotics 2
Class sedatives and hypnotics 2
 
Pharmacotherapy of Parkinson’s disease
Pharmacotherapy of Parkinson’s diseasePharmacotherapy of Parkinson’s disease
Pharmacotherapy of Parkinson’s disease
 
Pharmacogenomics
PharmacogenomicsPharmacogenomics
Pharmacogenomics
 
Pharmacodynamics II Dose-Response Relationships
Pharmacodynamics II Dose-Response RelationshipsPharmacodynamics II Dose-Response Relationships
Pharmacodynamics II Dose-Response Relationships
 
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh VaghelaNeurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
Neurodegenerative Disorders Pharmacotherapy Dr Jayesh Vaghela
 
Antiinflammatory drugs - Pharmacology
Antiinflammatory drugs - PharmacologyAntiinflammatory drugs - Pharmacology
Antiinflammatory drugs - Pharmacology
 

En vedette

Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...
Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...
Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...
Govt Medical College & Hospital, Sector-32
 
MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...
MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...
MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...
Govt Medical College & Hospital, Sector-32
 
Respiratorysystemdock 131210122437-phpapp02
Respiratorysystemdock 131210122437-phpapp02Respiratorysystemdock 131210122437-phpapp02
Respiratorysystemdock 131210122437-phpapp02
Sayeed Ahmad
 
Newer immunosuppressive drugs in renal tranplantation
Newer immunosuppressive drugs in renal tranplantationNewer immunosuppressive drugs in renal tranplantation
Newer immunosuppressive drugs in renal tranplantation
Sanjeev Nair
 
hiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trialhiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trial
ARUP SAHA
 
Physiology copy - copy
Physiology   copy - copyPhysiology   copy - copy
Physiology copy - copy
Sayeed Ahmad
 
poster presentation.ppt BIOPHARMACEUTICALS.
poster presentation.ppt BIOPHARMACEUTICALS.poster presentation.ppt BIOPHARMACEUTICALS.
poster presentation.ppt BIOPHARMACEUTICALS.
Nadia Jawaid
 

En vedette (20)

Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...
Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...
Thalidomide & its derivatives by Dr. Harmanjit Singh, Department of Pharmacol...
 
Recent advances in Antibacterials by Dr.Harmanjit Singh, GMC, Patiala
Recent advances in Antibacterials by Dr.Harmanjit Singh, GMC, PatialaRecent advances in Antibacterials by Dr.Harmanjit Singh, GMC, Patiala
Recent advances in Antibacterials by Dr.Harmanjit Singh, GMC, Patiala
 
MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...
MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...
MANAGEMENT OF CHLOROQUINE RESISTANT MALARIA BY Dr.HARMANJIT SINGH , DEPARTMEN...
 
Management of rheumatoid arthritis .by Dr.Harmanjit Singh,GMC, Patiala
Management of rheumatoid arthritis .by Dr.Harmanjit Singh,GMC, PatialaManagement of rheumatoid arthritis .by Dr.Harmanjit Singh,GMC, Patiala
Management of rheumatoid arthritis .by Dr.Harmanjit Singh,GMC, Patiala
 
Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology  Monoclonal Antibodies and their role in Pharmacology
Monoclonal Antibodies and their role in Pharmacology
 
Mood disorders
Mood disordersMood disorders
Mood disorders
 
Evaluation of Drugs used in CCF
Evaluation of Drugs used in CCFEvaluation of Drugs used in CCF
Evaluation of Drugs used in CCF
 
Respiratorysystemdock 131210122437-phpapp02
Respiratorysystemdock 131210122437-phpapp02Respiratorysystemdock 131210122437-phpapp02
Respiratorysystemdock 131210122437-phpapp02
 
Newer immunosuppressive drugs in renal tranplantation
Newer immunosuppressive drugs in renal tranplantationNewer immunosuppressive drugs in renal tranplantation
Newer immunosuppressive drugs in renal tranplantation
 
Magnetism 3243
Magnetism 3243Magnetism 3243
Magnetism 3243
 
Recent advances in hplc and gc
Recent advances in hplc and gcRecent advances in hplc and gc
Recent advances in hplc and gc
 
Anti malarial models
Anti malarial modelsAnti malarial models
Anti malarial models
 
Alternative medicines
Alternative medicinesAlternative medicines
Alternative medicines
 
hiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trialhiv and new category of anti hiv drugs in clinical trial
hiv and new category of anti hiv drugs in clinical trial
 
Anticoagulant
AnticoagulantAnticoagulant
Anticoagulant
 
Physiology copy - copy
Physiology   copy - copyPhysiology   copy - copy
Physiology copy - copy
 
poster presentation.ppt BIOPHARMACEUTICALS.
poster presentation.ppt BIOPHARMACEUTICALS.poster presentation.ppt BIOPHARMACEUTICALS.
poster presentation.ppt BIOPHARMACEUTICALS.
 
Newer advances in la
Newer advances in laNewer advances in la
Newer advances in la
 
Newer antibiotics
Newer antibioticsNewer antibiotics
Newer antibiotics
 
Newer Psychoactive Substances & Club Drugs
Newer Psychoactive Substances & Club DrugsNewer Psychoactive Substances & Club Drugs
Newer Psychoactive Substances & Club Drugs
 

Similaire à Dr. harman vasopeptidase inhibition

Renin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone systemRenin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone system
軒名 林
 

Similaire à Dr. harman vasopeptidase inhibition (20)

ARNI in Heart Failure Management
ARNI in Heart Failure ManagementARNI in Heart Failure Management
ARNI in Heart Failure Management
 
Hypertension according to latest clinical advances
Hypertension according to latest clinical advances Hypertension according to latest clinical advances
Hypertension according to latest clinical advances
 
2. Antihypertensive Drugs-MSN.pdf
2. Antihypertensive Drugs-MSN.pdf2. Antihypertensive Drugs-MSN.pdf
2. Antihypertensive Drugs-MSN.pdf
 
Cardio-Renal Protection Through Renin–Angiotensin–Aldosterone System Inhibition
Cardio-Renal Protection Through Renin–Angiotensin–Aldosterone System InhibitionCardio-Renal Protection Through Renin–Angiotensin–Aldosterone System Inhibition
Cardio-Renal Protection Through Renin–Angiotensin–Aldosterone System Inhibition
 
Rupajit Bhattacharjee hypertension management
Rupajit Bhattacharjee hypertension management Rupajit Bhattacharjee hypertension management
Rupajit Bhattacharjee hypertension management
 
Abnormalities of cardiac hormones...pdf
Abnormalities of cardiac hormones...pdfAbnormalities of cardiac hormones...pdf
Abnormalities of cardiac hormones...pdf
 
Antihypertensive drugs.pdf
Antihypertensive drugs.pdfAntihypertensive drugs.pdf
Antihypertensive drugs.pdf
 
Antihypertensive mbbs copy
Antihypertensive mbbs   copyAntihypertensive mbbs   copy
Antihypertensive mbbs copy
 
PATHOPHYSILOGY OF HYPERTENSION
PATHOPHYSILOGY OF HYPERTENSIONPATHOPHYSILOGY OF HYPERTENSION
PATHOPHYSILOGY OF HYPERTENSION
 
Reaction Paper On Ramipril
Reaction Paper On RamiprilReaction Paper On Ramipril
Reaction Paper On Ramipril
 
Antihipertensivos
AntihipertensivosAntihipertensivos
Antihipertensivos
 
A2
A2A2
A2
 
PAH management
PAH managementPAH management
PAH management
 
Renin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone systemRenin-Angiotensin Aldosterone system
Renin-Angiotensin Aldosterone system
 
Innovations in the Diagnosis and Treatment of Chronic Heart Failure
Innovations in the Diagnosis and Treatment of Chronic Heart FailureInnovations in the Diagnosis and Treatment of Chronic Heart Failure
Innovations in the Diagnosis and Treatment of Chronic Heart Failure
 
Hypertension+clinical
Hypertension+clinicalHypertension+clinical
Hypertension+clinical
 
Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system
 
TỐI ƯU HÓA ĐIỀU TRỊ TĂNG HUYẾT ÁP VỚI THUỐC CHẸN THỤ THỂ AT1 TRONG LIỆU PHÁP ...
TỐI ƯU HÓA ĐIỀU TRỊ TĂNG HUYẾT ÁP VỚI THUỐC CHẸN THỤ THỂ AT1 TRONG LIỆU PHÁP ...TỐI ƯU HÓA ĐIỀU TRỊ TĂNG HUYẾT ÁP VỚI THUỐC CHẸN THỤ THỂ AT1 TRONG LIỆU PHÁP ...
TỐI ƯU HÓA ĐIỀU TRỊ TĂNG HUYẾT ÁP VỚI THUỐC CHẸN THỤ THỂ AT1 TRONG LIỆU PHÁP ...
 
hypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacologyhypertension anesthesia, general management. antihypertensive pharmacology
hypertension anesthesia, general management. antihypertensive pharmacology
 
Recent Advancements in the treatment of Hypertension.
Recent Advancements  in the treatment of Hypertension.Recent Advancements  in the treatment of Hypertension.
Recent Advancements in the treatment of Hypertension.
 

Dr. harman vasopeptidase inhibition

  • 1. Vasopeptidase Inhibition: A New Direction in Cardiovascular Treatment . By: Dr. HARMANJIT SINGH MD STUDENT , GMC , PATIALA
  • 2.
  • 3.
  • 4.
  • 5. Treatment strategies by risk stratification and risk group categories in patients with hypertension BP stages (mm Hg) Treatment Strategy Risk Group A Risk Group B Risk Group C High-Normal (130-139 / 85-89) Lifestyle modification Lifestyle modification Drug therapy, Lifestyle modification Stage 1 (140-159 / 90-99) Lifestyle modification upto 12 months Lifestyle modification upto 6 months (patients with multiple factors should receive drug therapy + lifestyle modification) Drug therapy, lifestyle modification Stage 2 & 3 (> 160 / > 100) Drug therapy, lifestyle modification Drug therapy + lifestyle modification Drug therapy + lifestyle modification
  • 6.
  • 7.
  • 8. Figure 1 showing role of RAS system in cardiovascular disease
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17. Figure 2 showing the benefits of inhibiting NEP
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23. Figure 3 showing combined pathways involved in vasopeptidase inhibition
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.  
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41.